Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen M Sheldrake

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Organic & Biomolecular Chemistry|November 21, 2007
Kinetic and thermodynamic control of axial chirality in biaryl-derived fused oxazolidine lactams exploiting a centre-axis relay of unit efficiencyDavid J Edwards, David House, Helen M Sheldrake, et al.
Antioxidants (Basel, Switzerland)|April 29, 2025
Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic AcidDania Alhyari, Nidal A Qinna, Helen M Sheldrake, et al.
Chemical Communications (Cambridge, England)|October 18, 2011
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activityKlaus Pors, Paul M Loadman, Steven D Shnyder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2013
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxinsSandra Travica, Klaus Pors, Paul M Loadman, et al.
Cancers|August 26, 2023
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer TherapyMark Sutherland, Andrew Gordon, Fatemah O F O Al-Shammari, et al.
Medchemcomm|November 2, 2019
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinityAna R N Santos, Helen M Sheldrake, Ali I M Ibrahim, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compoundsNatalia Ortuzar, Kersti Karu, Daniela Presa, et al.
RSC Medicinal Chemistry|September 16, 2024
Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonistsAdam Throup, Manar Saleh Zraikat, Andrew Gordon, et al.
Molecular Cancer Therapeutics|October 4, 2012
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladderMark Sutherland, Jason H Gill, Paul M Loadman, et al.
Journal of Medicinal Chemistry|July 13, 2013
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activityHelen M Sheldrake, Sandra Travica, Inger Johansson, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Organic & Biomolecular Chemistry|November 21, 2007
Kinetic and thermodynamic control of axial chirality in biaryl-derived fused oxazolidine lactams exploiting a centre-axis relay of unit efficiencyDavid J Edwards, David House, Helen M Sheldrake, et al.
Antioxidants (Basel, Switzerland)|April 29, 2025
Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic AcidDania Alhyari, Nidal A Qinna, Helen M Sheldrake, et al.
Chemical Communications (Cambridge, England)|October 18, 2011
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activityKlaus Pors, Paul M Loadman, Steven D Shnyder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2013
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxinsSandra Travica, Klaus Pors, Paul M Loadman, et al.
Cancers|August 26, 2023
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer TherapyMark Sutherland, Andrew Gordon, Fatemah O F O Al-Shammari, et al.
Medchemcomm|November 2, 2019
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinityAna R N Santos, Helen M Sheldrake, Ali I M Ibrahim, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compoundsNatalia Ortuzar, Kersti Karu, Daniela Presa, et al.
RSC Medicinal Chemistry|September 16, 2024
Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonistsAdam Throup, Manar Saleh Zraikat, Andrew Gordon, et al.
Molecular Cancer Therapeutics|October 4, 2012
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladderMark Sutherland, Jason H Gill, Paul M Loadman, et al.
Journal of Medicinal Chemistry|July 13, 2013
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activityHelen M Sheldrake, Sandra Travica, Inger Johansson, et al.
Pageof 2